Who is sponsoring NCT05101057?

NCT05101057 is sponsored by Encore Medical, L.P..

What drugs are being tested in NCT05101057?

Interventions in NCT05101057: SpinalogicTM Bone Graft Stimulator.

What condition does NCT05101057 study?

NCT05101057 studies Degeneration of Cervical Intervertebral Disc.

Is NCT05101057 still recruiting?

NCT05101057 is currently status unknown. Last updated 7 December 2021.

Last reviewed 2021-12-07 · How we verify

NCT05101057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Retrospective Study to Examine the Effect of CMF Stimulation on Primary ACDF Patients

Status unknown Last updated 7 December 2021

What this trial tests

trial testing SpinalogicTM Bone Graft Stimulator in Degeneration of Cervical Intervertebral Disc in 400 participants. Status unknown.

Timeline

15 November 2021

Primary endpoint
1 March 2022

1 June 2022

Quick facts

Lead sponsor	Encore Medical, L.P.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	400
Start date	15 November 2021
Primary completion	1 March 2022
Estimated completion	1 June 2022
Sites	2 locations across United States

Drugs / interventions tested

SpinalogicTM Bone Graft Stimulator

Conditions studied

Degeneration of Cervical Intervertebral Disc — all drugs for Degeneration of Cervical Intervertebral Disc →

Sponsor

Encore Medical, L.P.

Who can join

Adults 18 to 75, any sex, with Degeneration of Cervical Intervertebral Disc. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective parallel group comparison study to support expansion of the indication of the company's FDA approved Spinalogic™ device to include the cervical spine. The SpinalogicTM device was initially approved by FDA as an adjunct to one- or two-level lumbar fusion (P910066/S011). It is a non-invasive bone growth stimulator (BGS) that generates a combined magnetic field (CMF) that has been proven to accelerate bone healing and fusion in the lumbar spine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Encore Medical, L.P. trials

Trials by the same sponsor.

NCT03711175 — The Influence of Repairing the Sub-scapularis on Outcomes After Reverse Arthroplasty · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05101057 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Encore Medical, L.P.
Last refreshed: 7 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05101057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing